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Methotrexate is a folate analog that is used in the treatment of cancers (e.g. acute
lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, and colon cancer) and
autoimmune diseases (e.g. rheumatoid arthritis, Crohn’s disease, and psoriasis). In the
treatment of autoimmune diseases, methotrexate is usually administrated orally or
subcutaneously, whereas in the cancer treatment, it can be given orally, intramuscularly, as
intrathecal injections, or as intravenous infusions (up to 12 g/m2) [1-3]. The
pharmacokinetics and pharmacodynamics of methotrexate show large interpatient variability
regardless of the route of administration or disease being treated [4-6]. The goal of this study
is to provide an introduction to methotrexate pharmacogenomics, showing the candidate
genes in the PharmGKB methotrexate pathway (Fig. 1), important variants (Tables 1 and 2),
discussing key knowledge, and pointing to more in-depth resources.
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The interindividual variability in methotrexate pharmacokinetics can be explained partially
by genetic variations in membrane transporter proteins with an affinity for methotrexate
[4,89]. In the gastrointestinal tract, methotrexate is absorbed through active transport
mediated by the reduced folate carrier (SLC19A1) and possibly also by the proton-coupled
folate transporter SLC46A1 (HCP1, PCFT) at the apical membrane of enterocytes [90].
Furthermore, the bioavailability of methotrexate after oral dosing may be affected by ABC
transporters, which can move methotrexate out of the enterocytes and back into the intestinal
tract (ABCC2, ABCB1, and ABCG2) or into the blood (ABCC1 and ABCC3) [91-93].
Systemic clearance of methotrexate happens primarily through renal glomerular filtration
and active secretion over the proximal tubular cells. Several renal transporter proteins have
an affinity for methotrexate (SLC22A6, SLC22A8, SLC19A1, ABCG2, ABCC2, and
ABCC4), and single nucleotide polymorphisms (SNPs) in ABCC2 have been associated
with delayed methotrexate clearance [53,89,94-98]. Hepatic uptake of methotrexate involves
the SLCO1B1 and SLCO1B3 transporters, in which SNPs have recently been found to
explain up to 10% of the interpatient variability in the clearance of high-dose methotrexate
[4,99-101]. Most of the methotrexate in hepatocytes reenters the blood circulation by
transporter proteins (ABCC3 and ABCC4) in the basolateral membrane, and only a small
portion of the methotrexate is excreted into the bile duct by the ABCC2 and ABCB1
transporters [102-105]. Inside the hepatocytes, aldehyde oxidase can convert methotrexate to
7-hydroxymethotrexate, a metabolite that is eliminated by the same route as methotrexate.
At the blood–brain barrier, ABC transporters with affinities for methotrexate are located in
endothelial cells, but the effect of facilitated transport of methotrexate out of the
cerebrospinal fluid remains to be unclear [106].
The pharmacodynamic profile of methotrexate can, to a large extent, be explained by its
interactions with enzymes in the folate pathway. The effects on methotrexate response of
variations in these genes have been extensively studied in cancer treatments [107]. At
extracellular methotrexate concentrations below 20 μmol/l, methotrexate enters cancer cells
primarily through the reduced folate carrier (SLC19A1) [108,109], whereas efflux across the
cell membrane is mediated by various ABC transporters; variations in these genes are
known mechanisms of drug resistance in cancer cells [110]. Inside the cells, methotrexate is
converted to active methotrexate polyglutamates (MTXPGs) by folylpolyglutamate
synthetase, which adds glutamate residues to methotrexate [111]. The primary action of
methotrexate is inhibition of the enzyme dihydrofolate reductase (DHFR), which converts
dihydrofolate to tetrahydrofolate (THF)[112]. Tetrahydrofolate is essential for de novo
purine synthesis, and in the biologically active form, 5-methyl-tetrahydrofolate, is an
important cofactor in one-carbon metabolism. The effect of methotrexate depends on the
function and expression of several other enzymes in the folate pathway, including
methylenetetrahydrofolate dehydrogenase (MTHFD1), 5,10-methylenetetrahydrofolate
reductase (MTHFR), and thymidylate synthetase (TYMS). Compared with methotrexate, the
active metabolites, MTXPGs induce stronger inhibition of the target enzymes (i.e. TYMS
and DHFR) and further inhibit key enzymes such as phosphoribosylglycinamide
formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole
synthetase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP
cyclohydrolase (ATIC) in the de novo purine synthesis pathway. MTXPG inhibition results
in decreased protein and DNA methylation in addition to impaired DNA formation and
repair. MTXPG levels are sustained inside the cells for a longer time than those of
methotrexate; degradation of MTXPGs to methotrexate depends on the activity of the
lysosomal enzyme γ-glutamyl hydrolase, which catalyzes the removal of polyglutamates
[113-115]. MTXPGs have been investigated in relation to clinical outcomes in rheumatoid
arthritis (RA) and juvenile idiopathic arthritis (JIA). Specifically, higher concentrations of
long-chain MTXPGs have been associated with favorable outcomes in RA [116] and risk of
gastrointestinal and hepatic toxicity in JIA [117].
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Gene expression and genetic variation in candidate genes have been studied extensively in
relation to many methotrexate response measures, including MTXPG accumulation (γ-
glutamyl hydrolase, folylpolyglutamate synthetase, and SLC19A1) [108,118,119], reduction
in tumor size (SLC19A1 and DHFR) [120], toxicity (MTHFR, and TYMS) [11,15], and
relapse (DHFR, TYMS, MTHFR, DHFR, and SLC19A1) [29,37,40,45,54,87,121].
Conflicting results among studies suggest that the effects of genetic variation are therapy
dependent and probably reflect the route of administration, dose, and duration of
methotrexate treatment [37,40]. Although these studies have contributed to our
understanding of the effects of Methotrexate and the molecular mechanisms involved in
drug resistance, no genetic variant has yet been prospectively evaluated as a predictor of an
outcome in a clinical trial.
Genome-wide studies have linked genes outside the folate pathway to the pharmacokinetics
and effects of methotrexate; many of these genes have not been analyzed earlier in studies
using the candidate approach. A recent study analyzed the association between MTXPG
accumulation and genetic variations such as leukemic cell gene expression, somatic copy
number variation, and SNPs [122]. Six genes on chromosome 18 (FHOD3, IMPA2, ME2,
SLC39A6, SMAD2, and SMAD4) and one on chromosome 10 (RASSF4) were found to be
associated with in-vivo intracellular accumulation of MTXPG in leukemic cells in all three
categories of genetic variation. In another genome-wide study of patients with acute
lymphoblastic leukemia, in-vivo response to MTX was found to be significantly associated
with the expression of genes in the nucleotide pathway (e.g. TYMS), but also with genes
involved in cell proliferation and apoptosis, and DNA repair and replication in the leukemic
cells [123]. Finally, a genome-wide association study that assessed the link between
inherited genomic variation and initial treatment response in patients with acute
lymphoblastic leukemia showed 14 SNPs significantly associated with both treatment
response and methotrexate clearance or MTXPG accumulation in leukemic cells [124]; early
treatment response assessed by eradication of leukemic cells is strongly associated with cure
rates and is therefore considered an important clinical phenotype.
No genome-wide association studies have yet been carried out in patients with rheumatoid
arthritis, but inherited variations in most genes from the folate pathway have been examined
in relation to methotrexate treatment response and toxicity [12,35]. However, to see a
clinically relevant effect of genetic variants in the folate, purine, and pyrimidine pathways, it
seems crucial to study gene–gene interactions; it has been suggested that the effects of
individual SNPs are enhanced when they occur in combination with other common SNPs in
these pathways [1]. Combinations of SNPs in the genes ATIC and adenosine receptor 2a
have been associated with differential MTXPG concentrations in JIA [117]. The anti-
inflammatory effect of methotrexate is further thought to be mediated through interaction
with the adenosine biosynthesis pathway [125]. MTXPGs inhibit the enzyme ATIC, which
after a cascade of events leads to the accumulation of the anti-inflammatory molecule
adenosine; SNPs in genes from the adenosine biosynthesis pathway (i.e. ATIC, inosine
triphosphatase, and adenosine monophosphate deaminase 1) have been found to predict the
efficacy of methotrexate treatment for RA and JIA [1,62,76,126].
Regardless of disease, it seems clear that future studies should continue to examine the
combined effect of variations in multiple genes to characterize the extent of genomic
determinants on variation in the pharmacokinetics and pharmacodynamics of methotrexate.
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Stylized cell showing candidate genes involved in pharmacokinetics and pharmacodynamics
of methotrexate. A fully interactive version is available online at
http://www.pharmgkb.org/do/serve?objId=PA2039&objCls=Pathway, and includes
additional views that show transport and action in different cell types.
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